Climb Bio Inc
CLYMHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeClimb Bio Inc operates in the Biotechnology space. Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company carries a $585.3M market cap, placing it firmly in the small-cap category. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Market Cap
$585.3M
Beta
-0.03
P/E (TTM)
—
P/E (Fwd)
-10.16
EPS (TTM)
$-0.82
EPS (Fwd)
$-1.00
ROE
-27.1%
ROA
-18.4%
Cash
$183.1M
Total Debt
$1.3M
Free CF
-$34.0M
52W Change
385.2%
Annual Financials
Cash vs Debt
Where CLYM stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CLYM finished 16.41% below its 150-day moving average ($11.64) and 3.76% below its 200-day moving average ($10.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CLYM overbought or oversold?
At the October 20, 2026 close, CLYM's RSI(14) was 27.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Climb Bio Inc holds $183.1M in cash against $1.3M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$34.0M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -27.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
CLYM's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, CLYM has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CLYM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.